SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001213900-21-036849
Filing Date
2021-07-14
Accepted
2021-07-14 13:59:16
Documents
16

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS ea144134-424b4_unicycive.htm 424B4 1518096
2 GRAPHIC image_001.jpg GRAPHIC 11465
3 GRAPHIC image_002.jpg GRAPHIC 45192
4 GRAPHIC image_003.jpg GRAPHIC 111047
5 GRAPHIC image_004.jpg GRAPHIC 64679
6 GRAPHIC image_005.jpg GRAPHIC 146890
7 GRAPHIC image_006.jpg GRAPHIC 31421
8 GRAPHIC image_007.jpg GRAPHIC 25838
9 GRAPHIC image_009.jpg GRAPHIC 49390
10 GRAPHIC image_010.jpg GRAPHIC 66947
11 GRAPHIC image_011.jpg GRAPHIC 68014
12 GRAPHIC image_012.jpg GRAPHIC 51166
13 GRAPHIC image_013.jpg GRAPHIC 52744
14 GRAPHIC image_014.jpg GRAPHIC 145070
15 GRAPHIC image_015.jpg GRAPHIC 27670
16 GRAPHIC image_016.jpg GRAPHIC 74548
  Complete submission text file 0001213900-21-036849.txt   2859975
Mailing Address 5150 EL CAMINO REAL, SUITE A-32 LOS ALTOS CA 94022
Business Address 5150 EL CAMINO REAL, SUITE A-32 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-256367 | Film No.: 211089919
SIC: 2834 Pharmaceutical Preparations